← Eichor
Condition: Carbapenem Resistant Enterobacteriaceae Infection Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Carbapenem Resistant Enterobacteriaceae Infection

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumo
Phase N/A · 1 location(s) · Fujian Medical University Union Hospital · NCT07086391EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
Phase 4 · 4 location(s) · National University of Singapore · NCT05979545Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated
NA · 1 location(s) · Hanoi University of Public Health · NCT05871476FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae
Phase 1/Phase 2 · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT04759001Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae I
NA · 15 location(s) · Southeast University, China · NCT06051513Safety and Efficacy of Fecal Microbiota Transplantation
NA · 1 location(s) · Chinese University of Hong Kong · NCT04014413Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children
Phase N/A · 1 location(s) · Children's Hospital of Fudan University · NCT04535661Further MT for Antibiotic-Resistant Bacterial Colonization
Phase 2 · 6 location(s) · Emory University · NCT05835206FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae
Phase 1/Phase 2 · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05791396Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infecti
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT07089186
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.